Core Insights - The Zacks Medical - Outpatient and Home Healthcare industry is experiencing a significant shift towards digital healthcare, driven by rising demand for telemedicine and AI-powered services, particularly due to an aging global population and increasing healthcare costs [1][4][9]. Industry Overview - The industry includes companies providing outpatient care and home healthcare services, utilizing advanced medical technologies for diagnosis and treatment. The sector has shown steady growth post-pandemic, supported by innovation and the shift towards value-based care models [3][6]. - The global home healthcare market was valued at $390.24 billion in 2023, with an expected CAGR of approximately 7.9% from 2024 to 2030 [1]. Major Trends - **Aging Population**: The growing elderly population is a primary driver for home healthcare services, increasing the demand for chronic disease management and rehabilitation [4]. - **Cost Effectiveness**: Outpatient clinics offer cost-effective care, supported by financial incentives from health plans and government programs [5]. - **AI Integration**: AI is enhancing healthcare delivery, with outpatient companies utilizing automated systems for better patient outcomes and efficiency [7]. - **Technological Advancements**: Virtual assistants and chatbots are becoming integral in patient care, aiding in appointment scheduling and medication compliance [8]. Challenges - **Staffing Shortages**: The U.S. healthcare sector faces significant staffing shortages, particularly among home health aides, exacerbated by high burnout rates [10]. - **Tariff Impact**: New U.S. tariffs have increased costs for imported medical supplies, straining home healthcare providers and leading to operational challenges [11]. Market Performance - The industry has outperformed its sector but underperformed compared to the S&P 500, gaining 6.8% over the past year versus the S&P 500's 12.1% gain [14]. - The industry is currently trading at a forward P/E of 19.8X, lower than the S&P 500's 22.3X [18]. Notable Companies - **Quest Diagnostics**: Expected revenue growth of 9.2% for 2025, with a strong return on equity (ROE) of 15.1% [22][23]. - **Encompass Health**: Anticipated revenue growth of 9.5% for 2025, with an ROE of 17.6% [25][26]. - **The Pennant Group**: Projected revenue growth of 23.3% for 2025, with an ROE of 10.7% [29][30]. - **DaVita**: Expected revenue growth of 5.2% for 2025, with a notably high ROE of 176.1% [33][34].

Here are two stocks with buy rank and strong momentum characteristics for investors to consider today, May 29th:Alexander's (ALX) : This real estate investment trust which is engaged in leasing, managing, developing and redeveloping properties, has a Zacks Rank #1(Strong Buy), and witnessed the Zacks Consensus Estimate for its current year earnings increasing 10.3% over the last 60 days.Alexander's shares gained 5% over the last three month compared with the S&P 500’s gain of 0.6%. The company possesses a M ...

Core Insights - MarketAxess reported revenue of $208.58 million for the quarter ended March 2025, a decrease of 0.8% year-over-year, with EPS at $1.87 compared to $1.92 in the same quarter last year [1] - The reported revenue fell short of the Zacks Consensus Estimate of $210.63 million, resulting in a surprise of -0.97%, while the EPS exceeded the consensus estimate of $1.82 by +2.75% [1] Financial Performance Metrics - Average Variable Transaction Fee Per Million - Credit was $139, below the five-analyst average estimate of $143.75 [4] - Average Daily Volume - Total reached $42.91 billion, surpassing the five-analyst average estimate of $40.74 billion [4] - Average Daily Volume - Total credit trading was $15.92 billion, slightly below the estimated $16.04 billion [4] - Average Daily Volume - Total rates trading was $26.98 billion, exceeding the five-analyst average estimate of $24.70 billion [4] - Revenues from Information services were $12.90 million, slightly below the estimate of $12.99 million, but represented an increase of +8.6% year-over-year [4] - Revenues from Commissions totaled $181.34 million, compared to the average estimate of $185.39 million, reflecting a -1.9% change year-over-year [4] - Revenues from Technology services were $3.24 million, slightly below the estimate of $3.29 million, with a year-over-year increase of +14.4% [4] - Revenues from Post-trade services were $11.09 million, compared to the average estimate of $11.14 million, representing a +3.3% change year-over-year [4] - Total commission revenue from variable transaction fees - Rates was $6.92 million, exceeding the four-analyst average estimate of $6.71 million, with a year-over-year change of +33.9% [4] - Total commission revenue from variable transaction fees - Credit was $135.84 million, below the estimated $139.51 million, reflecting a -4% change year-over-year [4] - Total commission revenue from fixed distribution fees was $33.35 million, slightly above the four-analyst average estimate of $32.36 million, with no change year-over-year [4] Stock Performance - MarketAxess shares returned +11% over the past month, outperforming the Zacks S&P 500 composite's +10.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Electronic trading platform MarketAxess Holdings Inc. (MKTX) is set to report first-quarter 2025 results on May 7, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $1.82 per share on revenues of $210.6 million. (See the Zacks Earnings Calendar to stay ahead of market-making news.)First-quarter earnings estimates have been revised downward over the past 60 days. The bottom-line projection indicates a decrease of 5.2% from the year-ag ...

Wall Street analysts expect MarketAxess (MKTX) to post quarterly earnings of $1.82 per share in its upcoming report, which indicates a year-over-year decline of 5.2%. Revenues are expected to be $210.63 million, up 0.2% from the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company announc ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 5th:GeneDx Holdings Corp. (WGS) : This genomics-related diagnostic and information services company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 12.4% over the last 60 days.GeneDx’s shares gained 8.2% over the last three months compared with the S&P 500’s decline of 6.5%. The company possesses a Momentum Score  of A.Eagle Bancorp Montana, Inc ...

Core Insights - CoStar Group reported revenue of $732.2 million for the quarter ended March 2025, reflecting an 11.6% increase year-over-year and exceeding the Zacks Consensus Estimate of $719.37 million by 1.78% [1] - The company's EPS was $0.14, up from $0.10 in the same quarter last year, representing a surprise of 27.27% compared to the consensus estimate of $0.11 [1] Revenue Breakdown - CoStar's revenue from its core business was $265.10 million, slightly above the average estimate of $264.81 million, marking a year-over-year increase of 5.9% [4] - Information Services generated $39.80 million, exceeding the estimated $36.30 million, with a year-over-year growth of 20.6% [4] - Other Marketplaces reported $44.80 million, significantly higher than the estimated $29.55 million, showing a year-over-year increase of 46.4% [4] - LoopNet's revenue was $72.80 million, slightly below the estimate of $73.38 million, with a year-over-year growth of 5.4% [4] - Residential revenue reached $27.20 million, below the estimate of $28.70 million, but still reflecting a substantial year-over-year increase of 46.2% [4] - Multifamily revenue was $282.50 million, close to the estimate of $283.47 million, with a year-over-year growth of 10.9% [4] Stock Performance - CoStar's shares have returned 3.2% over the past month, outperforming the Zacks S&P 500 composite, which declined by 0.8% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

CME Group (CME) reported first-quarter 2025 operating income of $2.80 per share, which beat the Zacks Consensus Estimate by 0.4%. The bottom line improved 12% year over year. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.).Quarterly results benefited from improving revenues, driven by higher clearing and transaction fees as well as market data and information services fees.  Increased volatility drove volumes.Performance in DetailCME Group’s revenues of $1.6 billion increased 10.4% ...